METIS TECHBIO-P (07666) saw its stock price soar by 5.53% during intraday trading on Monday, marking a significant upward movement.
The surge appears to be driven by the company's announcement of a comprehensive strategic technology cooperation agreement with Sandstone Biotech, a firm specializing in tumor immunocellular therapy. The collaboration focuses on immune-targeted lipid nanoparticle (LNP) delivery technology, leveraging METIS TECHBIO-P's AI-powered NanoForge platform to advance next-generation in vivo immunotherapy products. This partnership is part of the company's OpenCGT initiative, which has now seen cumulative collaboration values exceed RMB 60 billion.